LAVAL, QC, Aug. 14 /CNW/ – BioSyntech, Inc. (TSX: BSY – News) a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced that it has appointed Ms. Jeanne Bertonis, MBA, M.Sc., to the role of Chief Executive Officer. The Company previously announced that Ms. Bertonis was retained by BioSyntech as a consultant to assist the Company with its research and development, regulatory, strategic planning and business development strategies.
“Ms. Bertonis has 25 years of experience in the device, drug and biomaterials industries making her ideally suited to lead BioSyntech to achieve its commercialization objectives for our lead product for cartilage repair, BST-CarGel(R),” said Dr. Joyce Tsang, Director and Chair of the Governance Committee of BioSyntech. “Since joining the Company, she has worked effectively with BioSyntech as a consultant drawing on her extensive experience in the medical device sector and we are pleased that she will take a larger role in development of our Company as we look forward to the final results for our BST-CarGel(R) trial.”
“It has been my great pleasure this last month to work closely with the talented team of employees at BioSyntech,” said Ms. Jeanne Bertonis, Chief Executive Officer for BioSyntech. “I’ve been highly impressed with the clinical data that has been generated to date, and with the continued support of the Board of Directors I look forward to implementing the strategic initiatives that will be developed as a result of the work PricewaterhouseCoopers is conducting.”
